The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationship

Gene Colice, David Price, Maria Gerhardsson de Verdier, Karma Rabon-Stith, Christopher Ambrose, Katherine Cappell, Debra E. Irwin, Paul Juneau, Anna Vlahiotis, Respiratory Effectiveness Group (REG)

Research output: Contribution to journalArticle

6 Downloads (Pure)

Abstract

Rationale: DPP-4 may regulate immunological pathways implicated in asthma. Assessing whether DPP-4 inhibitor (DPP-4i) use might affect asthma control is clinically important because DPP-4i use in type 2 diabetes mellitus management (T2DM) is increasing. This study evaluated associations between DPP-4i use and asthma control.
Methods: This was a retrospective, observational, matched cohort study using administrative claims in the MarketScan® Commercial Claims and Encounters (Commercial) and Medicare Supplemental and Coordination of Benefits (Medicare Supplemental) databases. Adult asthma patients initiating an oral DPP-4i or a non-DPP-4i between November 1, 2006 and March 31, 2014 were included. Patients were followed for asthma-related outcomes for 12 months after initiation of the antidiabetes medication. Outcomes included risk-domain asthma control (RDAC), defined as no asthma hospitalizations, no lower respiratory tract infections, and no oral corticosteroid (OCS) prescriptions; overall asthma control (RDAC criteria plus limited short-acting beta agonist use); treatment stability (RDAC criteria plus no increase of ≥50% in inhaled corticosteroid dose or addition of other asthma therapy); and severe asthma exacerbation rates (asthma-related hospitalizations, emergency room visits, or acute treatments with OCS). Comparisons were made between two matched cohorts (DPP-4i vs. non-DPP-4i initiators) using multivariable logistic regression and generalized linear modeling. Covariates included baseline demographic and clinical characteristics related to asthma and T2DM.
Results: The adjusted odds of achieving RDAC (odds ratio [OR]: 1.05; 95% CI: 0.964 to 1.147), overall asthma control (OR: 1.04; 95% CI: 0.956 to 1.135), and treatment stability (OR: 1.04; 95% CI: 0.949 to 1.115) did not differ between the DPP-4i and non-DPP-4i cohorts. A difference was not found between cohorts in severe asthma exacerbation rates during the 12 months following initiation of antidiabetes treatment (mean = 0.32 vs. 0.34 exacerbations per subject-year, respectively; p=0.064).
Conclusion: Asthma control was similar between patients initiating DPP-4i and non-DPP-4i antidiabetes medications, suggesting no association between DPP-4i use and asthma control.
Original languageEnglish
Pages (from-to)231-240
Number of pages10
JournalPragmatic and Observational Research
Volume2017
Issue number8
DOIs
Publication statusPublished - 1 Dec 2017

Fingerprint

Asthma
Databases
Adrenal Cortex Hormones
Odds Ratio
Medicare
Type 2 Diabetes Mellitus
Hospitalization
Therapeutics
Respiratory Tract Infections
Prescriptions
Hospital Emergency Service
Cohort Studies
Logistic Models

Keywords

  • asthma control
  • DPP-4i
  • type 2 diabetes

Cite this

Colice, G., Price, D., Gerhardsson de Verdier, M., Rabon-Stith, K., Ambrose, C., Cappell, K., ... Respiratory Effectiveness Group (REG) (2017). The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationship. Pragmatic and Observational Research, 2017(8), 231-240. https://doi.org/10.2147/POR.S144018

The effect of DPP-4 inhibitors on asthma control : an administrative database study to evaluate a potential pathophysiological relationship. / Colice, Gene; Price, David; Gerhardsson de Verdier, Maria; Rabon-Stith, Karma; Ambrose, Christopher; Cappell, Katherine; Irwin, Debra E.; Juneau, Paul; Vlahiotis, Anna; Respiratory Effectiveness Group (REG).

In: Pragmatic and Observational Research, Vol. 2017, No. 8, 01.12.2017, p. 231-240.

Research output: Contribution to journalArticle

Colice, G, Price, D, Gerhardsson de Verdier, M, Rabon-Stith, K, Ambrose, C, Cappell, K, Irwin, DE, Juneau, P, Vlahiotis, A & Respiratory Effectiveness Group (REG) 2017, 'The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationship', Pragmatic and Observational Research, vol. 2017, no. 8, pp. 231-240. https://doi.org/10.2147/POR.S144018
Colice, Gene ; Price, David ; Gerhardsson de Verdier, Maria ; Rabon-Stith, Karma ; Ambrose, Christopher ; Cappell, Katherine ; Irwin, Debra E. ; Juneau, Paul ; Vlahiotis, Anna ; Respiratory Effectiveness Group (REG). / The effect of DPP-4 inhibitors on asthma control : an administrative database study to evaluate a potential pathophysiological relationship. In: Pragmatic and Observational Research. 2017 ; Vol. 2017, No. 8. pp. 231-240.
@article{8ee25a1b232b49339f0306c3b1a5c6c8,
title = "The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationship",
abstract = "Rationale: DPP-4 may regulate immunological pathways implicated in asthma. Assessing whether DPP-4 inhibitor (DPP-4i) use might affect asthma control is clinically important because DPP-4i use in type 2 diabetes mellitus management (T2DM) is increasing. This study evaluated associations between DPP-4i use and asthma control.Methods: This was a retrospective, observational, matched cohort study using administrative claims in the MarketScan{\circledR} Commercial Claims and Encounters (Commercial) and Medicare Supplemental and Coordination of Benefits (Medicare Supplemental) databases. Adult asthma patients initiating an oral DPP-4i or a non-DPP-4i between November 1, 2006 and March 31, 2014 were included. Patients were followed for asthma-related outcomes for 12 months after initiation of the antidiabetes medication. Outcomes included risk-domain asthma control (RDAC), defined as no asthma hospitalizations, no lower respiratory tract infections, and no oral corticosteroid (OCS) prescriptions; overall asthma control (RDAC criteria plus limited short-acting beta agonist use); treatment stability (RDAC criteria plus no increase of ≥50{\%} in inhaled corticosteroid dose or addition of other asthma therapy); and severe asthma exacerbation rates (asthma-related hospitalizations, emergency room visits, or acute treatments with OCS). Comparisons were made between two matched cohorts (DPP-4i vs. non-DPP-4i initiators) using multivariable logistic regression and generalized linear modeling. Covariates included baseline demographic and clinical characteristics related to asthma and T2DM.Results: The adjusted odds of achieving RDAC (odds ratio [OR]: 1.05; 95{\%} CI: 0.964 to 1.147), overall asthma control (OR: 1.04; 95{\%} CI: 0.956 to 1.135), and treatment stability (OR: 1.04; 95{\%} CI: 0.949 to 1.115) did not differ between the DPP-4i and non-DPP-4i cohorts. A difference was not found between cohorts in severe asthma exacerbation rates during the 12 months following initiation of antidiabetes treatment (mean = 0.32 vs. 0.34 exacerbations per subject-year, respectively; p=0.064). Conclusion: Asthma control was similar between patients initiating DPP-4i and non-DPP-4i antidiabetes medications, suggesting no association between DPP-4i use and asthma control.",
keywords = "asthma control, DPP-4i, type 2 diabetes",
author = "Gene Colice and David Price and {Gerhardsson de Verdier}, Maria and Karma Rabon-Stith and Christopher Ambrose and Katherine Cappell and Irwin, {Debra E.} and Paul Juneau and Anna Vlahiotis and {Respiratory Effectiveness Group (REG)}",
note = "Acknowledgments The authors acknowledge Koustubh Ranade (MedImmune, Gaithersburg, MD, USA) and Stephen Johnston, a member of the steering committee who was employed by Truven Health Analytics at the time the study was conducted, for their contributions to this study . Truven Health Analytics, an IBM Company, received funding from AstraZeneca in relation to this study. This work was previously presented as a poster at the annual international conference of the American Thoracic Society, May 19–24, 2017, Washington, DC (Colice G, et al. The Effect of Dipeptidyl-Peptidase-4 Inhibitors on Asthma Control: An Administrative Database Study to Evaluate a Potential Pathophysiological Relationship. Am J Respir Crit Care Med. 2017;195:A3050).",
year = "2017",
month = "12",
day = "1",
doi = "10.2147/POR.S144018",
language = "English",
volume = "2017",
pages = "231--240",
journal = "Pragmatic and Observational Research",
issn = "1179-7266",
publisher = "Dove Medical Press Ltd.",
number = "8",

}

TY - JOUR

T1 - The effect of DPP-4 inhibitors on asthma control

T2 - an administrative database study to evaluate a potential pathophysiological relationship

AU - Colice, Gene

AU - Price, David

AU - Gerhardsson de Verdier, Maria

AU - Rabon-Stith, Karma

AU - Ambrose, Christopher

AU - Cappell, Katherine

AU - Irwin, Debra E.

AU - Juneau, Paul

AU - Vlahiotis, Anna

AU - Respiratory Effectiveness Group (REG)

N1 - Acknowledgments The authors acknowledge Koustubh Ranade (MedImmune, Gaithersburg, MD, USA) and Stephen Johnston, a member of the steering committee who was employed by Truven Health Analytics at the time the study was conducted, for their contributions to this study . Truven Health Analytics, an IBM Company, received funding from AstraZeneca in relation to this study. This work was previously presented as a poster at the annual international conference of the American Thoracic Society, May 19–24, 2017, Washington, DC (Colice G, et al. The Effect of Dipeptidyl-Peptidase-4 Inhibitors on Asthma Control: An Administrative Database Study to Evaluate a Potential Pathophysiological Relationship. Am J Respir Crit Care Med. 2017;195:A3050).

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Rationale: DPP-4 may regulate immunological pathways implicated in asthma. Assessing whether DPP-4 inhibitor (DPP-4i) use might affect asthma control is clinically important because DPP-4i use in type 2 diabetes mellitus management (T2DM) is increasing. This study evaluated associations between DPP-4i use and asthma control.Methods: This was a retrospective, observational, matched cohort study using administrative claims in the MarketScan® Commercial Claims and Encounters (Commercial) and Medicare Supplemental and Coordination of Benefits (Medicare Supplemental) databases. Adult asthma patients initiating an oral DPP-4i or a non-DPP-4i between November 1, 2006 and March 31, 2014 were included. Patients were followed for asthma-related outcomes for 12 months after initiation of the antidiabetes medication. Outcomes included risk-domain asthma control (RDAC), defined as no asthma hospitalizations, no lower respiratory tract infections, and no oral corticosteroid (OCS) prescriptions; overall asthma control (RDAC criteria plus limited short-acting beta agonist use); treatment stability (RDAC criteria plus no increase of ≥50% in inhaled corticosteroid dose or addition of other asthma therapy); and severe asthma exacerbation rates (asthma-related hospitalizations, emergency room visits, or acute treatments with OCS). Comparisons were made between two matched cohorts (DPP-4i vs. non-DPP-4i initiators) using multivariable logistic regression and generalized linear modeling. Covariates included baseline demographic and clinical characteristics related to asthma and T2DM.Results: The adjusted odds of achieving RDAC (odds ratio [OR]: 1.05; 95% CI: 0.964 to 1.147), overall asthma control (OR: 1.04; 95% CI: 0.956 to 1.135), and treatment stability (OR: 1.04; 95% CI: 0.949 to 1.115) did not differ between the DPP-4i and non-DPP-4i cohorts. A difference was not found between cohorts in severe asthma exacerbation rates during the 12 months following initiation of antidiabetes treatment (mean = 0.32 vs. 0.34 exacerbations per subject-year, respectively; p=0.064). Conclusion: Asthma control was similar between patients initiating DPP-4i and non-DPP-4i antidiabetes medications, suggesting no association between DPP-4i use and asthma control.

AB - Rationale: DPP-4 may regulate immunological pathways implicated in asthma. Assessing whether DPP-4 inhibitor (DPP-4i) use might affect asthma control is clinically important because DPP-4i use in type 2 diabetes mellitus management (T2DM) is increasing. This study evaluated associations between DPP-4i use and asthma control.Methods: This was a retrospective, observational, matched cohort study using administrative claims in the MarketScan® Commercial Claims and Encounters (Commercial) and Medicare Supplemental and Coordination of Benefits (Medicare Supplemental) databases. Adult asthma patients initiating an oral DPP-4i or a non-DPP-4i between November 1, 2006 and March 31, 2014 were included. Patients were followed for asthma-related outcomes for 12 months after initiation of the antidiabetes medication. Outcomes included risk-domain asthma control (RDAC), defined as no asthma hospitalizations, no lower respiratory tract infections, and no oral corticosteroid (OCS) prescriptions; overall asthma control (RDAC criteria plus limited short-acting beta agonist use); treatment stability (RDAC criteria plus no increase of ≥50% in inhaled corticosteroid dose or addition of other asthma therapy); and severe asthma exacerbation rates (asthma-related hospitalizations, emergency room visits, or acute treatments with OCS). Comparisons were made between two matched cohorts (DPP-4i vs. non-DPP-4i initiators) using multivariable logistic regression and generalized linear modeling. Covariates included baseline demographic and clinical characteristics related to asthma and T2DM.Results: The adjusted odds of achieving RDAC (odds ratio [OR]: 1.05; 95% CI: 0.964 to 1.147), overall asthma control (OR: 1.04; 95% CI: 0.956 to 1.135), and treatment stability (OR: 1.04; 95% CI: 0.949 to 1.115) did not differ between the DPP-4i and non-DPP-4i cohorts. A difference was not found between cohorts in severe asthma exacerbation rates during the 12 months following initiation of antidiabetes treatment (mean = 0.32 vs. 0.34 exacerbations per subject-year, respectively; p=0.064). Conclusion: Asthma control was similar between patients initiating DPP-4i and non-DPP-4i antidiabetes medications, suggesting no association between DPP-4i use and asthma control.

KW - asthma control

KW - DPP-4i

KW - type 2 diabetes

U2 - 10.2147/POR.S144018

DO - 10.2147/POR.S144018

M3 - Article

VL - 2017

SP - 231

EP - 240

JO - Pragmatic and Observational Research

JF - Pragmatic and Observational Research

SN - 1179-7266

IS - 8

ER -